Trial Profile
Single-institutional observational surveillance of nivolumab for previously treated with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 26 May 2016 New trial record